%PDF-1.4
%
31 0 obj
<>
endobj
28 0 obj
<>
endobj
81 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-02T12:53:01Z
2024-03-28T09:40:23-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T09:40:23-07:00
application/pdf
Heather
201219.nov
uuid:64e7f844-1dd2-11b2-0a00-a509278d5b00
uuid:64e7f846-1dd2-11b2-0a00-1e0000000000
endstream
endobj
17 0 obj
<>
endobj
18 0 obj
<>
endobj
32 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
99 0 obj
[103 0 R]
endobj
100 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.0249 Tw 8 0 0 8 72 714.5293 Tm
[(Kaplan S. Ef)17.8 (fects of long-term administration of methotrexate on)]TJ
0 -1.25 TD
[(bone mineral density in rheumatoid arthritis. Calcif )17.7 (T)34.9 (issue Int)]TJ
0 Tw T*
(1999;64:100-1. )Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(14.)-625.1 (Katz JN, Lebof)17.7 (f MS, )17.7 (W)79.7 (ade JP)110.7 (, Brown EM, Liang MH. Ef)17.7 (fect of)]TJ
0 Tc 1.875 -1.25 Td
(methotrexate on bone density and calcium homeostasis in)Tj
T*
(rheumatoid arthritis [abstract]. Clin Res 1989;37:509A.)Tj
-1.875 -1.25 Td
[(15.)-625 (Bianchi ML, Bardare M, Cimaz R, Galbiati E, Corona F)79.8 (, Cherubini)]TJ
-0.00011 Tc 1.875 -1.25 Td
[(R. Does methotrexate have an ef)17.7 (fect on bone mass? [abstract]. )]TJ
0 Tc T*
[(J Bone Miner Res 1996;1)36.9 (1:S225.)]TJ
-1.875 -1.25 Td
[(16.)-625 (Buckley LM, Lieb ES, Cartularo KS, )17.7 (V)111.1 (acek PM, Cooper SM.)]TJ
1.875 -1.25 Td
[(Ef)17.8 (fects of low dose methotrexate on the bone mineral density of)]TJ
T*
(patients with rheumatoid arthritis. J Rheumatol 1997;24:1489-94.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(17.)-625.1 (Pascaretti Ch, Perroux-Goumy L, Masson C, Legrand E, Bregreon)]TJ
0 Tc 1.875 -1.25 Td
[(C, )54.9 (Audran M. Methotrexate osteopathy in rheumatoid arthritis: a)]TJ
T*
(two year longitudinal and prospective study [abstract]. J Bone Miner)Tj
T*
[(Res 1996;1)36.9 (1:S513.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(18.)-625.1 (Mazzantini M, DiMunno O, Incerti-V)110.7 (ecchi L, Pasero G. )17.7 (V)111 (ertebral)]TJ
0 Tc 1.875 -1.25 Td
(bone mineral density changes in female rheumatoid arthritis patients)Tj
T*
(treated with low-dose methotrexate. Clin Exp Rheumatol)Tj
0 Tw T*
(2000;18:327-31.)Tj
0.02499 Tw -1.875 -1.25 Td
[(19.)-625 (Ferraccioli G, Casatta L, Bartoli E. Increase of bone mineral density)]TJ
1.875 -1.25 Td
(and anabolic variables in patients with rheumatoid arthritis resistant)Tj
T*
[(to methotrexate after cyclosporin )54.9 (A)-219.8 (therapy)64.9 (. J Rheumatol)]TJ
0 Tw T*
(1996;23:1539-42.)Tj
-0.00011 Tc 0.02499 Tw 31.125 28.75 Td
[(20.)-625.1 (Dequeker J, Maenaut K, )17.7 (V)111 (erwilghen J, )17.7 (W)79.7 (esthovens R. Osteoporosis)]TJ
0 Tc 1.875 -1.25 Td
(in rheumatoid arthritis. Clin Exp Rheumatol 1995;13 Suppl 12:)Tj
-0.00011 Tc 0 Tw T*
(S21-6.)Tj
0 Tc 0.02499 Tw -1.875 -1.25 Td
[(21.)-625 (Smolen JS, Breedveld FC, Eberl G, et al. )17.8 (V)111.1 (alidity and reliability of)]TJ
1.875 -1.25 Td
[(the 28-joint count for the assessment of rheumatoid arthritis activity)64.9 (.)]TJ
T*
(Arthritis Rheum 1995;38:38-43.)Tj
-0.00011 Tc -1.875 -1.25 Td
[(22.)-625.1 (Marks R, Barton SP)110.7 (, Shuttleworth D, et al. )54.8 (Assessment of disease)]TJ
0 Tc 1.875 -1.25 Td
[(progress in psoriasis. )54.8 (Arch Dermatol 1989;125:235-40.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(23.)-625.1 (El Miedany )36.8 (YM, )54.8 (Abubakr IH, El Baddini M. Ef)17.7 (fect of low dose)]TJ
0 Tc 1.875 -1.25 Td
(methotrexate on markers of bone metabolism in patients with)Tj
T*
(rheumatoid arthritis. J Rheumatol 1998;25:2083-7.)Tj
-1.875 -1.25 Td
[(24.)-625 (Suzuki )36.8 (Y)129.2 (, )17.7 (T)69.8 (a)0.1 (nihara M, Ichikawa )36.8 (Y)129.1 (, et al. Periarticular osteopenia in)]TJ
1.875 -1.25 Td
(adjuvant arthritis: Role of interleukin-1 in decreased osteogenic and)Tj
T*
[(increased resorptive potential of bone marrow cells. )54.8 (Ann Rheum Dis)]TJ
0 Tw T*
(1995;54:484-90.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(25.)-625.1 (Preston SJ, Clifton-Bligh P)110.7 (,)-0.1 ( Laurent MR, Jackson C, Mason RS.)]TJ
0 Tc 1.875 -1.25 Td
[(Ef)17.8 (fect of methotrexate and sulphasalazine on UMR 106 rat)]TJ
T*
(osteosarcoma cells. Br J Rheumatol 1997;36:178-84.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Cranney)54.9 (, et al: Effect of MTX on bone)]TJ
0 Tw 60.9375 -0.0313 Td
(2399)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 58.38 407.5 -10.83 re
f*
0.5 w
102.25 58.38 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2001. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
70 0 obj
<>
endobj
86 0 obj
<>
endobj
39 0 obj
<>
endobj
34 0 obj
<>
endobj
36 0 obj
<>
endobj
64 0 obj
<>stream
HVpMg}9ބ(ysHInxD+TQ{!h*Rdehbu[!um);]۱ء muTYܳsT;|B hj((JfwqwY(TnK@MUs;R%-Z1%Fp$ 9eƞ=./
vЧW9QG5)sul-@xmfq Jڑ̫̕П<[7=4/zWΜ3"Zl}Ͽ{Ʉ(ue$jhT Γn[!-Po%hDž\ztAX0E*<
XFH@>fcqv)b(/ASCۿr*Gq308,k38%>Vk
#^vTC̱1uy9"?-Gq:):
X
C<]QclzE<!";bZ~3WO%l#1s:|ceb5XGoh+!3 Cw"b53/p*(ObX/ҫen5FdC+8
Y7$5-{>gg.Ph)"D/⢌qҐ%%]TOW5ohu;gYOEegnUL"^n/b챘c96l ۅrOIwp(DGHHnVm Z F*HTbXM{'+/}r\(}<+-$+.WwjdmVrzt';4.4)T:a9h+ͪZzvp%#0ؑtvuFpM3؛y:s#3